论文部分内容阅读
目的探讨周期特异性药物甲氨蝶呤(MTX)、来氟米特(LEF)与周期非特异性药物环磷酰胺(CTX)联合与两种周期特异性药物甲氨蝶呤与来氟米特(MTX+LEF)联合治疗类风湿关节炎(RA)临床疗效和安全性比较。方法将92例活动期RA患者随机分三组,MTX+CTX组36人,LEF+CTX组30人,LEF+MTX组26人。三组均治疗12周。观察三组治疗后的临床疗效和安全性。结果治疗12周后,联合CTX组(MTX+CTX、LEF+CTX)在DAS28、ESR、患者评估的疾病总体状况VAS评分、关节肿胀数、关节压痛数等临床及实验室指标均优于MTX+LEF组,差异均有统计学意义(P<0.05);联合CTX组不良反应少于MTX+LEF组,差异有统计学意义(P<0.05)。结论周期特异性药物(MTX、LEF)与周期非特异性药物(CTX)联合临床疗效好,不良反应小,安全性高。
Objective To investigate the effects of methotrexate (MTX), leflunomide (LEF) and cyclophosphamide (CTX) combined with two cycle-specific drugs methotrexate and leflunomide MTX + LEF) in the treatment of rheumatoid arthritis (RA) clinical efficacy and safety comparison. Methods 92 patients with active RA were randomly divided into three groups: 36 in MTX + CTX group, 30 in LEF + CTX group and 26 in LEF + MTX group. All three groups were treated for 12 weeks. The clinical efficacy and safety of the three groups were observed. Results After treatment for 12 weeks, the clinical and laboratory indexes such as VAS score, joint swelling and joint tenderness in the combined disease group (MTX + CTX, LEF + CTX) at DAS28 and ESR were better than those of MTX + LEF group, the difference was statistically significant (P <0.05). The adverse reactions of combined CTX group were less than that of MTX + LEF group, the difference was statistically significant (P <0.05). Conclusion The combination of cyclophosphamide (MTX, LEF) and cyclophosphamide (CTX) has good clinical efficacy, less side effects and high safety.